3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Squamous Cell Carcinoma of Head and Neck
1
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms by Histologic Type
1
Neoplasms
1
Metastatic Neuroendocrine Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration-Resistant Prostate Cancer
1
Lymphoproliferative Disorders
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Lymphatic Diseases
1
Lung Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immune System Diseases
1
Gastro-enteropancreatic neuroendocrine tumor
1
Digestive System Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Biochemically Recurrent Prostate Carcinoma
1
AIDS-Related Complex
1
Interventions
relugolix
1
apalutamide
1
abiraterone
1
Prednisone
1
Methylprednisolone
1
Lutetium-177
1
Lutetium
1
Gonadotropin-Releasing Hormone
1
Docetaxel
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Metastatic Castration-Resistant Prostate Cancer
×
Lutetium-177
×
Clear all
NCT06531499
2025-12-31
RADIODOSE
Novartis
Phase 1
Recruiting
106 enrolled